The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along with eight other societies on recommendations for multimodality imaging in cardiac amyloidosis in the Journal of Nuclear Cardiology. ASNC assembled a writing team of 26 experts in cardiovascular imaging and amyloidosis representing these nine societies: the American College of Cardiology (ACC), the American Heart Association (AHA), the American Society of Echocardiography (ASE), the European Association of Nuclear Medicine (EANM), the Heart Failure Society of America (HFSA), the International Society of Amyloidosis (ISA), the Society of Cardiovascular Magnetic Resonance (SCMR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Emerging imaging methods have facilitated earlier diagnosis of cardiac amyloidosis and improved prognostication and management with new treatment options. The diagnostic criteria for cardiac amyloidosis, required updating to include these novel imaging tools.

The cath lab staff UH Portage Medical Center.
View of a Penumbra atherectomy system being used on a STEMI patient that had a 9 minute door-to-balloon time.

Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute ST-segment elevation myocardial infarction (STEMI). Previous studies have shown a strong association between urgent performance of primary PCI, as assessed in terms of the door-to-balloon time (D2B), the interval from the patient's arrival at the hospital to inflation of the balloon to restore flow, and reduced mortality.
ESC President Barbara Casadei, M.D., DPhil, FRCP, FESC, a British Heart Foundation Professor and an honorary consultant cardiologist at the John Radcliffe Hospital in Oxford, speaks at a press conference at the 2019 ESC Congress. #ESC19 #ESC2019

September 9, 2019 — More than 33,000 health professionals gathered over five days to attend the 2019 European Society of Cardiology (ESC) congress in Paris. The event included more than 600 expert sessions covering the entire spectrum of cardiovascular medicine. There also were six Hot Line sessions showcasing 28 key clinical trials and 13 Late-breaking Science sessions, which both attracted large crowds.

September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart failure with reduced ejection fraction (HFrEF)with and without diabetes. The late-breaking results of the DAPA-HF trial were presented in a Hot Line Session at European Society of Cardiology (ESC) 2019 congress together with the World Congress of Cardiology.

Society for Cardiovascular Magnetic Resonance (SCMR)

Society for Cardiovascular Magnetic Resonance (SCMR), from February 12-15, 2020 in Orlando, Florida.

Business-to-business communications company Scranton Gillette Communications has named Diane Vojcanin as vice president, group publisher, healthcare group. Additionally, the company is announcing that Andreja Slapsys will serve as a healthcare group integrated media consultant.

Haojie Wang, M.D., director of advanced cardiovascular MRI and a member of the heart valve clinic at Baylor Scott White Heart Hospital, Dallas. His hospital installed a dedicated cardiac Siemens 1.5T MRI scanner in 2018 because MRI offers soft tissue visualization not available on CT or ultrasound.
A cardiac MRI perfusion assessment on Fujifilm's analysis software. CMR imaging assessment.
A cardiac MRI perfusion assessment on Fujifilm's analysis software. CMR imaging assessment.

Traditionally, computed tomography (CT) and ultrasound have been the workhorse imaging modalities in the world of cardiology. While the advantages of these modalities have afforded them a prominent position in cardiac imaging, magnetic resonance imaging (MRI) is promising because it directly addresses the shortcomings of both modalities — cardiac magnetic resonance (CMR) provides excellent soft tissue contrast without giving any ionizing radiation dose to the patient. 

Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at 12 months, according to newly released data from the BIOSTEMI trial.1 At the European Society of Cardiology (ESC) 2019 Congress, Aug. 31-Sept. 4 in Paris, France, Juan Fernando Iglesias, M.D., Ph.D., Geneva University Hospitals, Geneva, Switzerland, unveiled the results of the randomized controlled trial (RCT) in a late-breaking session. The results have also been published in The Lancet.

 

Abbott announced the launch of the company's TRILUMINATE Pivotal trial evaluating the safety and effectiveness of its TriClip transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation (TR). This is the first pivotal Investigational Device Exemption (IDE) trial in the U.S. to evaluate a catheter-based, non-surgical treatment for patients with severe TR – a condition in which the valve does not close properly, allowing blood to flow backward into the heart, which forces the heart to work harder. In severe cases, this condition can potentially lead to heart failure if left untreated.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now